IGM Biosciences pivoted to autoimmune disease, reducing R&D expenses. The company reported a net loss of $61.4 million. CEO ...

MOUNTAIN VIEW, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced ...

Since it has a market capitalisation of US$939m, IGM Biosciences' US$176m in cash burn equates to about 19% of its market value. As a result, we'd venture that the company could raise more cash for ...

Analyst Michael Ulz of Morgan Stanley maintained a Hold rating on IGM Biosciences (IGMS – Research Report), retaining the price target of ...

In a report released on November 8, Brian Abrahams from RBC Capital maintained a Buy rating on IGM Biosciences (IGMS – Research Report), ...

Nov. 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial ...

Shares of IGM Biosciences, Inc. (NASDAQ:IGMS – Get Free Report) dropped 7.8% on Friday .The stock traded as low as $12.82 and last traded at $13.25. Approximately 108,339 shares changed hands ...

Igm Biosciences ( (IGMS)) has released its Q3 earnings. Here is a breakdown of the information Igm Biosciences presented to its investors. IGM Biosciences, a clinical-stage biotechnology company ...

Igm Biosciences (IGMS) has disclosed a new risk, in the Share Price & Shareholder Rights category. Igm Biosciences faces significant risks that could adversely impact its business and financial ...